195 related articles for article (PubMed ID: 11737893)
1. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.
Correa I; Plunkett T
Breast Cancer Res; 2001; 3(6):399-403. PubMed ID: 11737893
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN; Sotiriadou NN; Gritzapis AD; Sotiropoulou PA; Perez SA; Cacoullos NT; Papamichail M
Cancer Immunol Immunother; 2006 Jan; 55(1):85-95. PubMed ID: 15948002
[TBL] [Abstract][Full Text] [Related]
3. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL; Disis ML
Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
[TBL] [Abstract][Full Text] [Related]
4. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccines targeting the HER2/neu oncogenic protein.
Disis ML; Schiffman K
Semin Oncol; 2001 Dec; 28(6 Suppl 18):12-20. PubMed ID: 11774201
[TBL] [Abstract][Full Text] [Related]
6. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
7. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
Knutson KL; Block MS; Norton N; Erskine CL; Hobday TJ; Dietz AB; Padley D; Gustafson MP; Puglisi-Knutson D; Mangskau TK; Chumsri S; Dueck AC; Karyampudi L; Wilson G; Degnim AC
Clin Cancer Res; 2020 Mar; 26(5):1045-1053. PubMed ID: 31757875
[TBL] [Abstract][Full Text] [Related]
8. Peptide vaccines in breast cancer: The immunological basis for clinical response.
Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
[TBL] [Abstract][Full Text] [Related]
9. Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
Azuma K; Shichijo S; Shomura H; Matsueda S; Fujii T; Itoh K
Breast Cancer Res Treat; 2004 Jul; 86(1):19-29. PubMed ID: 15218358
[TBL] [Abstract][Full Text] [Related]
10. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Disis ML; Gooley TA; Rinn K; Davis D; Piepkorn M; Cheever MA; Knutson KL; Schiffman K
J Clin Oncol; 2002 Jun; 20(11):2624-32. PubMed ID: 12039923
[TBL] [Abstract][Full Text] [Related]
11. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
[TBL] [Abstract][Full Text] [Related]
13. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
15. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.
Peoples GE; Goedegebuure PS; Smith R; Linehan DC; Yoshino I; Eberlein TJ
Proc Natl Acad Sci U S A; 1995 Jan; 92(2):432-6. PubMed ID: 7831305
[TBL] [Abstract][Full Text] [Related]
16. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment.
Zhou Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6711-6718. PubMed ID: 36692548
[TBL] [Abstract][Full Text] [Related]
19. HER2-Based Immunotherapy for Breast Cancer.
Cui N; Shi J; Yang C
Cancer Biother Radiopharm; 2018 Jun; 33(5):169-175. PubMed ID: 29874101
[TBL] [Abstract][Full Text] [Related]
20. Developing anti-HER2 vaccines: Breast cancer experience.
Al-Awadhi A; Lee Murray J; Ibrahim NK
Int J Cancer; 2018 Nov; 143(9):2126-2132. PubMed ID: 29693245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
